Premium
Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis
Author(s) -
Koskela K.,
Pelliniemi TT.,
Rajamäki A.,
Pulkki K.,
Remes K.
Publication year - 2000
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2000.90167.x
Subject(s) - oncostatin m , medicine , multiple myeloma , interleukin 6 , clinical significance , gastroenterology , disease , cytokine , pathology
Since high levels of serum IL‐6 predict a poor prognosis of patients with multiple myeloma (MM), we investigated if a related cytokine, oncostatin M (OSM), correlates with clinical or biochemical findings or has prognostic significance in patients with MM. Among 82 newly diagnosed MM patients, OSM was detected in the sera in 45 (55%). Serum OSM had a borderline statistical correlation with serum IL‐6 ( r =0.198, p =0.074) and C‐reactive protein ( r =0.199, p =0.074) concentrations. However, OSM did not have prognostic significance alone or in combination with other factors. The median survival of patients with detectable serum OSM concentration was 41 months (range 2–124 months) and of OSM negative patients 35 months (1–75 months). Serum OSM concentration was not associated with clinical factors or severity of bone disease at diagnosis. We conclude that serum OSM concentration is not a prognostic factor in MM patients.